Affiliations: Zentrum für klinische Pathologie, Robert Bosch
Hospital Stuttgart | Novartis Forschungsinstitut, A-1235 Vienna |
Note: [] Address for correspondence: Dr. P. Fritz Robert Bosch
Krankenhaus Auerbachstr. 110 71376 Stuttgart Germany
Abstract: We have investigated the expression of Lewis Y (a member of the
Lewis blood group family) with regard to both its diagnostic use in surgical
pathology and its therapeutic application. A total of 228 tumor samples
(carcinoma, benign and malignant soft tissue tumors) were included in the
study. By using an ABC immunohistochemical method, we demonstrated that the
expression of Lewis Y is highly correlated with an epithelial origin of a
tumor. With a sensitivity of 90% and specificity of 96% a positive Lewis Y
immunohistochemical reaction was found to discriminate epithelial tumors from
non-epithelial tumors . Monoclonal antibodies raised against Lewis Y and
humanized can be used in tumor therapy. Prior to a therapeutic application the
expression of Lewis Y in different tumor types and the amount of positive tumor
cells has to be known. From our data we conclude that epithelial, but not
mesenchymal tumors may be suitable for immunotherapy with humanized monoclonal
LewisY antibodies. An immunohistochemical assessment of the LewisY expression
should be carried out prior to an application of humanized LewisY antibodies.
Of the investigated tumors, especially breast cancer may be taken into
consideration for the first clinical trial.
Keywords: Lewis Y antigens, epithelial tumors, immunotherapy